• About us
• Contact

Advertisement

Organisation › Details

Biodesix Inc.

Biodesix is a lung cancer diagnostic solutions company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex® strategy integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours. The Nodify XL2™ nodule test, which will be commercially available in the second half of 2019, evaluates the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges. *

 

	Start	2005-01-01 established
	Industry	molecular diagnostics
	Industry 2	MALDI-TOF mass spectrometry technology
	Person	Brunel, David (Biodesix 200810 CEO)
	Person 2	Hutton, Scott (Biodesix 201803– COO before Spectranetics + Medtronic)
	Region	Boulder, CO
	Country	United States (USA)
	Street	2970 Wilderness Place Suite 100
	City	80301 Boulder, CO
	Tel	+1-303-417-0500
		Address record changed: 2020-12-02
Basic data	Employees	D: 101 to 500 (2015-10-09)
		* Document for »About Section«: Oncimmune Holdings plc. (6/28/19). "Press Release: Oncimmune Secures Strategic Commercialisation Agreement for EarlyCDT Lung in the US with Biodesix, Inc.". London.
		Record changed: 2023-07-10

Advertisement

More documents for Biodesix Inc.

• [1] Oncimmune Holdings plc. (6/28/19). "Press Release: Oncimmune Secures Strategic Commercialisation Agreement for EarlyCDT Lung in the US with Biodesix, Inc.". London....
• [2] MRM Proteomics Inc.. (1/28/19). "Press Release: MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics". Montréal, QC & Boulder, CO....
• [3] Biodesix, Inc.. (7/9/18). "Press Release: Biodesix Extends Lung Franchise with Acquisition of Integrated Diagnostics". Boulder, CO....
• [4] Biodesix, Inc.. (4/30/18). "Press Release: New Data Demonstrate the Biodesix VeriStrat Liquid Biopsy Test Reliably Informs Lung Cancer Treatment Decisions". Boulder, CO....
• [5] Biodesix, Inc.. (3/20/18). "Press Release: Biodesix Announces Biomarker Research Collaboration with Checkmate Pharmaceuticals"....
• [6] Biodesix, Inc.. (3/5/18). "Press Release: Biodesix Raises Add-On to Series G, Enters into Debt Refinancing Agreement with Innovatus Capital Partners, Scott Hutton Joins Biodesix". Boulder, CO....
• [7] Biodesix, Inc.. (5/22/17). "Press Release: New Study Shows Advanced Diagnostic Tests, Including the VeriStrat Test, Can Help Physicians Improve Cancer Care Planning and Reach Quality Measures For Patients"....
• [8] Biodesix, Inc.. (4/5/17). "Press Release: Biodesix Presents Data from Three Studies at AACR Annual Meeting". Boulder, CO....
• [9] Biodesix, Inc.. (3/20/17). "Press Release: Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber. Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients"....
• [10] Biodesix, Inc.. (3/9/17). "Press Release: Biodesix and Progenetics Announce Distribution Agreement for Israel". Boulder, CO....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.